Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LEO Pharma A/S

http://www.leo-pharma.com

Latest From LEO Pharma A/S

Keeping Track: US FDA Says Yes To AZ’s Farxiga In CKD And ADC’s Zynlonta, But No To Leo’s Tralokinumab, Chiesi’s Pegunigalsidase

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Review

FDA Thwarts Leo Pharma's US Launch Plans For Tralokinumab

A week after getting the thumbs-up from the CHMP for tralokinumab, the Denmark-based dermatology specialist has been hit by a complete response letter from US regulators requesting more data about a device component of the IL-13 inhibitor.

Dermatology Complete Response Letters

Market Intel: Medtechs, Surgeons Embrace ‘Virtual Operating Theater’ As New Reality

In this first part of a three-part series on the “Future of Surgery” we introduce three companies that developed telehealth platforms allowing for virtual collaborations during live surgeries. The second part will discuss AI, VR and AR in the OR.

Market Intelligence Telehealth

EU Thumbs Up Signals First-Ever Approval For Leo’s Tralokinumab

Leo’s moderate-to-severe atopic dermatitis drug is set to be approved for the first time worldwide.

Europe Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • LEO Pharma Inc.
    • Peplin, Inc.
UsernamePublicRestriction

Register